TITLE

Kidney transplant drug approved

AUTHOR(S)
Traynor, Kate
PUB. DATE
August 2011
SOURCE
American Journal of Health-System Pharmacy;8/1/2011, Vol. 68 Issue 15, p1372
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that the FDA has approved belatacept injection, marketed as Nulojix, for the prevention of acute organ rejection in kidney transplant patients. Its labeling states that the drug increases patients' danger for posttransplant lymphoproliferative disorder (PTLD), a blood malignancy which affects the central nervous system (CNS).The article also discusses the recommended dosage and other labeling details for the drug, and the adverse events observed.
ACCESSION #
63621415

 

Related Articles

  • FDA on Cladribine.  // Momentum (19403410);Summer2011, Vol. 4 Issue 3, p23 

    The article reports on the ruling by the U.S. Federal Drug Administration (FDA) declining marketing approval for oral Cladribine intended for relapsing forms of multiple sclerosis (MS).

  • Multipl Sklerozda FDA Onaylı Ä°lk Oral Ajan: Fingolimod. AKMAN-DEM#305;R, Gülşen // Archives of Neuropsychiatry / Noropsikiatri Arsivi;Dec2011 Supplement, Vol. 48, p64 

    Disease-modifying drugs (DMDs) are being used in multiple sclerosis (MS) for the last 20 years. Until recently, only interferon beta and glatiramer acetate preparations were available, which are administered by repetitive injections. In the last quarter of 2010, the USA Food and Drug...

  • FDA approves first oral MS disease-modifier.  // Momentum (19403410);Winter2010/2011, Vol. 4 Issue 1, p21 

    The article announces the decision of the U.S. Food and Drug Administration (FDA) on Septembeer 21, 2010 to approve fingolimod capsules (Gilenya) as treatment of multiple sclerosis in relapsing forms.

  • A New Era: New Drugs, New Options, New Risks. King, Martha // Momentum (19403410);Spring2011, Vol. 4 Issue 2, p21 

    The article offers updates on multiple sclerosis (MS) management. It cites the case of Melissa Losasso who had side effects after taking drugs and a weekly injection under a clinical trial. The safety issues about the new drugs being developed for MS are discussed, including Gilenya and Tysabri...

  • Immunosuppressants.  // Reactions Weekly;9/3/2011, Issue 1367, p23 

    The article describes the clinical cases of four renal transplant patients who developed malignancies associated with their disused arteriovenous fistulae (AVF) while under immunosuppressant therapies.

  • Immunosuppressants.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p161 

    An abstract of the article "Aseptic arthritis due to parvovirus B19 infection immediately after kidney and pancreas transplantation" by A.A. Markova and others is presented.

  • New drugs.  // Drug Topics;6/1/98, Vol. 142 Issue 11, p83 

    Reports that in 1998 the United States Food and Drug Administration approved Novartis Pharmaceutical Corporation's drug Simulect, an immunosuppressant, for the prevention of acute rejection episodes in renal-transplant recipients. How this drug works; Recommended dosage for this drug;...

  • Some of the comers.  // Momentum (19403410);Spring2011, Vol. 4 Issue 2, p22 

    The article presents descriptions to drugs for multiple sclerosis (MS). It relates that gilenya can reduce relapse rate by 54% and slow progression of disability by 30% versus inactive placebo. Research confirmed that there were 58% fewer relapses and 32% less disability in a trial versus...

  • Diarrhea in a post-renal transplant child: Questions. Wiley, Jasmine; Shivaram, Pushpa; Resnick, Jeffrey; Fish, Daryl; Park, Roger; Haws, Robert // Pediatric Nephrology;Apr2015, Vol. 30 Issue 4, p589 

    The article presents a case study of a 14-year-old boy with the status of post-living relative renal transplant is presented. His past medical history includes bilateral Wilms tumor with multiple recurrences, subsequent bilateral nephrectomies and living relative renal transplant. On examining...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics